Pages that link to "Q34802314"

The following pages link to 4 years after withdrawal of rofecoxib: where do we stand today? (Q34802314):

Displaying 11 items.

• Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database (Q30990764) (← links)
• An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? (Q34083026) (← links)
• Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) andO2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as Safe Anti-Inflammatory, Analgesic, Antipyretic, Antioxidant Prodrugs (Q34257599) (← links)
• Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. (Q34305332) (← links)
• Salvianolic Acid B, a Potential Chemopreventive Agent, for Head and Neck Squamous Cell Cancer (Q34442838) (← links)
• Effect of ginger powder supplementation on nitric oxide and C-reactive protein in elderly knee osteoarthritis patients: A 12-week double-blind randomized placebo-controlled clinical trial (Q37074641) (← links)
• Rehabilitation after hip fracture (Q38155093) (← links)
• Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation (Q38332948) (← links)
• Design, synthesis and biological evaluation of novel 4-hydroxybenzene acrylic acid derivatives (Q83355371) (← links)
• [Problems of pain measurement and pain therapy in the elderly] (Q84569893) (← links)
• [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management] (Q87320656) (← links)